



UCB Annual General Meeting of Shareholders 2026

Brussels, Belgium – March 27, 2026, 7: 00 am (CET) – Regulated Information – UCB (Euronext Brussels: UCB) today announced the convening of its Annual General Meeting of Shareholders (the “General Meeting”), to be held on Thursday, 30 April 2026 at 11:00 CEST at its headquarters in Brussels, Belgium.

The full convening notice, including the agenda and participation formalities, is available at: <https://www.ucb.com/investors/UCB-shareholders/Shareholders-meeting-2026>.

Further to the General Meeting, there will be several changes to its Board of Directors.

The mandate of Professor Dame Kay Davies, independent director, will expire at the General Meeting and will not be renewed. After twelve years of service, including as Chair of the Governance, Nomination and Compensation Committee and as a member of the Scientific Committee, the Board expresses its deep appreciation for her contributions. Jonathan Peacock, Chair of the Board of UCB, commented: *“On behalf of the Board, I would like to express our sincere gratitude to Dame Kay Davies for her outstanding contribution over the past twelve years. Her scientific insight, thoughtful guidance and unwavering commitment have been instrumental to the Board’s work and to UCB’s long-term development.”*

UCB is also announcing with regret that Rodolfo J. Savitzky will step down from the Board, effective April 30, 2026, following the 2026 Annual General Meeting. This was agreed with UCB to support him as he pursues an executive function he recently assumed with another company. The Board wishes to express its appreciation to Rodolfo for his contributions and commitment during his tenure and extends its best wishes for his future endeavors

Finally, the Board of Directors proposes the renewal of the mandates of Jean-Christophe Tellier, Chief Executive Officer, and Cédric van Rijckevorsel as directors for a period of four years, until the close of the Annual General Meeting in 2030.

Participation and documentation

Shareholders wishing to participate in the General Meeting may attend in person or vote by proxy, including via the Lumi Connect platform. In order to do so, they must comply with the admission formalities by **24 April 2026, 15:00 CEST**, as described in the convening notice available at: <https://www.ucb.com/investors/UCB-shareholders/Shareholders-meeting-2026>

The record date is 16 April 2026 at 24:00 CEST.

Dividend

The Board of Directors proposes to pay a gross dividend of € 1.45 per share (gross), to be approved by the General Meeting.

- Ex-dividend: 4 May 2026
- Record date: 5 May 2026
- Payment: 6 May 2026

Coupon # 29 of UCB shares is payable at € 1.015 net per share after deduction of Belgian withholding tax of 30%*, via our paying agent, KBC Bank NV.

* Lower withholding tax rates may be applicable depending on the specific situation of each shareholder.

For further information, contact UCB:

Investor Relations

Antje Witte
T +32.2.559.94.14
antje.witte@ucb.com

Sahar Yazdian
T +32.2.559.91.37
Sahar.yazdian@ucb.com

Corporate Communications

Laurent Schots
T +32.2.559.92.64
laurent.schots@ucb.com

About UCB

UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 9 000 people in approximately 40 countries, the company generated revenue of € 7.7 billion in 2025. UCB is listed on Euronext Brussels (symbol: UCB).

Forward looking statements

This document contains forward-looking statements, including, without limitation, statements containing the words “potential”, “believes”, “anticipates”, “expects”, “intends”, “plans”, “seeks”, “estimates”, “may”, “will”, “continue” and similar expressions. These forward-looking statements are based on current plans, estimates and beliefs of management. All statements, other than statements of historical facts, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial information, expected legal, arbitration, political, regulatory or clinical results or practices and other such estimates and results. By their nature, such forward-looking statements are not guaranteeing future performance and are subject to known and unknown risks, uncertainties, and assumptions which might cause the actual results, financial condition, performance or achievements of UCB, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements contained in this document.

Important factors that could result in such differences include but are not limited to: global spread and impacts of wars, pandemics and terrorism, the general geopolitical environment, climate change, changes in general economic, business and competitive conditions, the inability to obtain necessary regulatory approvals or to obtain them on acceptable terms or within expected timing, costs associated with research and development, changes in the prospects for products in the pipeline or under development by UCB, effects of future judicial decisions or governmental investigations, safety, quality, data integrity or manufacturing issues, supply chain disruption and business continuity risks; potential or actual data security and data privacy breaches, or disruptions of UCB’s information technology systems, product liability claims, challenges to patent protection for products or product candidates, competition from other products including biosimilars or disruptive technologies/business models, changes in laws or regulations, exchange rate fluctuations, changes or uncertainties in laws and/or rules pertaining to tax and duties or the administration of such laws and/or rules, and hiring, retention and compliance of employees. There is no guarantee that new product candidates will be discovered or identified in the pipeline, or that new indications for existing products will be developed and approved. Movement from concept to commercial product is uncertain; preclinical results do not guarantee safety and efficacy of product candidates in humans. So far, the complexity of the human body cannot be reproduced in computer models, cell culture systems or animal models. The length of the timing to complete clinical trials and to get regulatory approval for product marketing has varied in the past and UCB expects similar unpredictability going forward. Products or potential products which are the subject of partnerships, joint ventures or licensing collaborations may be subject to disputes between the partners or may prove to be not as



UCB News

safe, effective or commercially successful as UCB may have believed at the start of such partnership. UCB's efforts to acquire other products or companies and to integrate the operations of such acquired companies may not be as successful as UCB may have believed at the moment of acquisition. Also, UCB or others could discover safety, side effects or manufacturing problems with its products and/or devices after they are marketed. The discovery of significant problems with a product similar to one of UCB's products that implicate an entire class of products may have a material adverse effect on sales of the entire class of affected products. Moreover, sales may be impacted by international and domestic trends toward managed care and health care cost containment, including pricing pressure, political and public scrutiny, customer and prescriber patterns or practices, and the reimbursement policies imposed by third-party payers as well as legislation affecting biopharmaceutical pricing and reimbursement activities and outcomes. Finally, a breakdown, cyberattack or information security breach could compromise the confidentiality, integrity and availability of UCB's data and systems.

Given these uncertainties, the public is cautioned not to place any undue reliance on such forward-looking statements. These forward-looking statements are made only as of the date of this document, and do not reflect any potential impacts from the evolving event or risk as mentioned above as well as any other adversity, unless indicated otherwise. The company continues to follow the development diligently to assess the financial significance of these events, as the case may be, to UCB.

UCB expressly disclaims any obligation to update any forward-looking statements in this document, either to confirm the actual results or to report or reflect any change in its forward-looking statements with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless such statement is required pursuant to applicable laws and regulations.